Your browser doesn't support javascript.

Portal de Pesquisa da BVS Enfermagem

Informação e Conhecimento para a Saúde

Home > Pesquisa > ()
XML
Imprimir Exportar

Formato de exportação:

Exportar

Email
Adicionar mais destinatários
| |

Structural inferences for Cholera toxin mutations in Vibrio cholerae.

Shamini, Gunasagaran; Ravichandran, Manickam; Sinnott, John T; Somboonwit, Charurut; Sidhu, Harcharan S; Shapshak, Paul; Kangueane, Pandjassarame.
Bioinformation ; 6(1): 1-9, 2011 Mar 02.
Artigo em Inglês | MEDLINE | ID: mdl-21464837
Cholera is a global disease that has persisted for millennia. The cholera toxin (CT) from Vibrio cholerae is responsible for the clinical symptoms of cholera. This toxin is a hetero-hexamer (AB(5)) complex consisting of a subunit A (CTA) with a pentamer (B(5)) of subunit B (CTB). The importance of the AB(5) complex for pathogenesis is established for the wild type O1 serogroup using known structural and functional data. However, its role is not yet documented in other known serogroups harboring sequence level residue mutations. The sequences for the toxin from different serogroups are available in GenBank (release 177). Sequence analysis reveals mutations at several sequence positions in the toxin across serogroups. Therefore, it is of interest to locate the position of these mutations in the AB(5) structure to infer complex assembly for its functional role in different serogroups. We show that mutations in the CTA are at the solvent exposed regions of the AB(5) complex, whereas those in the CTB are at the CTB/CTB interface of the homo-pentamer complex. Thus, the role of mutations at the CTB/CTB interface for B(5) complex assembly is implied. It is observed that these mutations are often non-synonymous (e.g. polar to non-polar or vice versa). The formation of the AB(5) complex involves inter-subunit residue-residue interactions at the protein-protein interfaces. Hence, these mutations, at the structurally relevant positions, are of importance for the understanding of pathogenesis by several serogroups. This is also of significance in the improvement of recombinant CT protein complex analogs for vaccine design and their use against multiple serogroups.